1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
AREV Life Sciences Global Corp.

AREV Life Sciences Global Corp.

AREV.CN
AREV Life Sciences Global Corp.CA flagCanadian Securities Exchange
0.09
CAD
- -
- -
2.84MMarket Cap

Total Valuation

AREV Life Sciences Global Corp. carries a market capitalization of 2.84M, placing it among publicly traded companies globally. Its enterprise value stands at 3.00M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.84M
Enterprise Value3.00M

Share Statistics

AREV Life Sciences Global Corp. currently has 31.76M shares outstanding.

Shares Outstanding31.76M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 396.35, and the price-to-book ratio stands at -0.69.

PE RatioN/A
PS Ratio396.35
PB Ratio-0.69
P/TBV Ratio-2.46
P/FCF Ratio-19.00
P/OCF Ratio-18.81

Enterprise Valuation

EV / Sales416.27
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

AREV Life Sciences Global Corp. maintains a current ratio of 0.05, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -12.51, indicating conservative leverage, while an interest coverage ratio of -35.16 demonstrates limited ability to service its debt obligations.

Current Ratio0.05
Quick Ratio0.04
Debt / Equity-12.51
Debt / EBITDA-1.04
Interest Coverage-35.16

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-83.46
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)41.53
Revenue Per EmployeeN/A
Employee CountN/A
Inventory TurnoverN/A

Stock Price Statistics

AREV Life Sciences Global Corp.'s stock has declined approximately -28% over the past 52 weeks. The 50-day moving average sits at 0.09, while the 200-day moving average is 0.09.

Beta (5Y)N/A
52-Week Price Change-28%
50-Day Moving Average0.09
200-Day Moving Average0.09
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, AREV Life Sciences Global Corp. generated 7,209.00 in revenue and converted that into -239,541.00 in net income, yielding earnings per share of -0.01. EBITDA reached -140,092.00, while operating income came in at -210,432.00.

Revenue7,209.00
Gross ProfitN/A
Operating Income-210,432.00
Pretax Income-239,541.00
Net Income-239,541.00
EBITDA-140,092.00
EBIT-210,432.00
Earnings Per Share (EPS)-0.01

Balance Sheet

AREV Life Sciences Global Corp. holds 1,818.00 in cash and equivalents against 145,461.00 in total debt, resulting in a net debt position of 143,643.00. Total book value stands at -4.16M, with working capital of -1.31M providing operational flexibility.

Cash & Cash Equivalents1,818.00
Total Debt145,461.00
Net Debt143,643.00
Equity (Book Value)-4.16M
Book Value Per Share-0.13
Working Capital-1.31M

Cash Flow

AREV Life Sciences Global Corp. produced -151,887.00 in operating cash flow over the past twelve months. After subtracting -1,477.00 in capital expenditures, free cash flow totaled -153,364.00 - equivalent to 0.00 per share.

Operating Cash Flow-151,887.00
Capital Expenditures-1,477.00
Free Cash Flow-153,364.00
FCF Per Share0.00

Margins

AREV Life Sciences Global Corp. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -2,919.02 and net profit margin of -3,322.80 provide insight into operational efficiency.

Gross Margin100.00
Operating Margin-2,919.02
Pretax Margin-3,322.80
Profit Margin-3,322.80
EBITDA Margin-1,943.29

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-4.90
FCF Yield-5.26

Stock Splits

AREV Life Sciences Global Corp.'s most recent stock split took place on March 19, 2020 with a 6:1 split ratio.

Last Split Date3/19/2020
Split Ratio6:1

Scores

AREV Life Sciences Global Corp. posts an Altman Z-Score of -126.61, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-126.61